Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in
the extra cellular domain of the human epidermal growth factor receptor (EGFR), inhibiting
tyrosine kinase activation. It has been approved to treat squamous cell carcinoma of head and
neck (SCCHN), glioma and nasopharyngeal carcinoma in different countries. Currently, the
registered clinical trials of Nimotuzumab combined with chemotherapy in advanced non-small
cell lung cancer, colorectal cancer, esophageal cancer and glioma have been approved and are
ongoing all over the investigators' country. The main purpose of this study is to evaluate
the pharmacokinetic characteristics of Nimotuzumab combined with Irinotecan in patients with
solid tumors.